Thus, experimental and human AIP/IgG4-RD are both characterized by enhanced expression of CXCL9, CXCL10, and CCL25 and such enhanced expression is attenuated by treatment. Here, CXCL9 is linked to immunoglobulin G4-related sclerosing disease.